A Type 2 Diabetes Study of the Longer-Term Glycemic Effect of AVANDAMET vs. Metformin

Completed · Phase 4 · Has a placebo group

Conditions studied: Diabetes Mellitus, Type 2

In brief

This study will evaluate the longer-term glycemic effect of two medicines approved for initial treatment of type 2 diabetes. The study consists of a 2 week screening period (2 study visits), followed by an 80 week double-blind treatment period (11 study visits). Also, a sub-study was included to look at changes in bone mineral density (BMD) at the lumbar spine.

Key facts

Study ID

NCT00386100

Run by

GlaxoSmithKline

People needed

688

Starts

2006-10-01

Expected to finish

2009-09-01

Last updated by the study team

2016-11-23

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• The subject provides written informed consent.
• The subject is male or female and 18 to 75 years of age at the time of pre-screening.
• The subject has an established clinical diagnosis of type 2 diabetes according to recommended guidelines (e.g., American Diabetes Association, International Diabetes Federation, World Health Organization, Canadian Diabetes Association, or American Association of Clinical Endocrinologists).
• The subject is currently treated with diet and exercise, and has not taken more than 2 weeks of an anti-diabetic monotherapy or insulin in the past 6 months.
• The subject has a BMI >25 kg/m2 at pre-screening.
• The subject has a Quest HbA1c 7.5% to 10.5% at pre-screening.
• The subject has a fasting capillary blood glucose 126 mg/dL (7mmol/L), as measured by the site staff at week 0.
• If the subject is a pre-menopausal female of child-bearing potential, she agrees to practice acceptable contraceptive measures (e.g. oral birth control pills, Norplant, Depo-Provera, an intrauterine device (IUD), a diaphragm with spermicide or a condom with spermicide, or abstinence) at least 1 month before screening, during the study, and for 30 days after the last dose of study medication is taken
• The subject is able and willing to perform self-monitoring of blood glucose as specified in this protocol.

You may not qualify if…

• The subject has taken an oral anti-diabetic monotherapy or insulin for more than 14 days in the past 6 months.
• The subject has presence of clinically significant renal or hepatic disease (serum creatinine 1.5 mg/dL (132.6 mol/L) for males and 1.4 mg/dL (123.8 mol/L) for females): ALT, AST, total bilirubin, or alkaline phosphatase >2.5 times the upper limit of the normal (ULN) reference range.
• The subject has anemia defined by hemoglobin concentration <11g/dL (110g/L) for males or <10g/dL (100g/L) for females.
• Presence of unstable or severe angina, coronary insufficiency or New York Heart Association (NYHA) class III-IV or any congestive heart failure requiring pharmacologic treatment.
• The subject has systolic blood pressure >160 mmHg or diastolic blood pressure >90 mmHg
• The subject has a chronic disease requiring intermittent or chronic treatment with oral, intravenous, or intra-articular corticosteroids (i.e., only use of topical, inhaled or nasal corticosteroids is permitted).
• The subject has acute or chronic metabolic acidosis or a history of diabetic ketoacidosis.
• The subject has a clinically significant abnormality which in the judgment of the investigator makes the subject unsuitable for inclusion in the study (e.g., physical examination, laboratory tests, or electrocardiogram, etc).
• The subject has used an investigational agent within 30 days or 5 half-lives (whichever was longer) prior to pre-screening.
• The subject is a female who is lactating, pregnant, or planned to become pregnant.
• The subject has a prior history of severe edema or a medically serious fluid related event (e.g., heart failure).
• The subject has a history of macular edema.
• The subject has significant hypersensitivity (e.g., difficulty swallowing, difficulty breathing, and tachycardia or skin reaction) to TZDs, biguanides, or compounds with similar chemical structures.
• The subject has a diagnosis of cancer (other than squamous, basal cell, or cervical cancer in-situ) in the past 3 years and is receiving treatment for cancer.
• The subject has a history or suspicion of drug abuse or alcohol abuse within the last 6 months.
• The subject is known to have severe lactose intolerance.
• The subject is not willing to comply with visits and procedures described in the protocol.
• The subject has a disease that may affect bone turnover including, but not limited to: Paget's disease, hypercalcemia, hypocalcemia, hyperparathyroidism, hyperthyroidism, osteomalacia, metastatic bone disease
• The subject has a weight of greater than 300 lbs (136.4 kg).
• The subject has received treatment with bisphosphonates (≥1 month cumulative treatment within the last 12 months) or fluoride (dose greater than 10mg/day within the previous 5 years).

Where it is running

• GSK Investigational Site — Gilbert, Arizona, United States
• GSK Investigational Site — Glendale, Arizona, United States
• GSK Investigational Site — Phoenix, Arizona, United States
• GSK Investigational Site — Tucson, Arizona, United States
• GSK Investigational Site — Tucson, Arizona, United States
• GSK Investigational Site — Alhambra, California, United States
• GSK Investigational Site — Artesia, California, United States
• GSK Investigational Site — Greenbrae, California, United States
• GSK Investigational Site — Roseville, California, United States
• GSK Investigational Site — Sacramento, California, United States
• GSK Investigational Site — Wheat Ridge, Colorado, United States
• GSK Investigational Site — Hialeah, Florida, United States
• GSK Investigational Site — Ocala, Florida, United States
• GSK Investigational Site — Kahului, Hawaii, United States
• GSK Investigational Site — Peoria, Illinois, United States
• GSK Investigational Site — Avon, Indiana, United States
• GSK Investigational Site — Evansville, Indiana, United States
• GSK Investigational Site — Evansville, Indiana, United States
• GSK Investigational Site — Indianapolis, Indiana, United States
• GSK Investigational Site — Waterloo, Iowa, United States
• GSK Investigational Site — Slidell, Louisiana, United States
• GSK Investigational Site — Sunset, Louisiana, United States
• GSK Investigational Site — Elkridge, Maryland, United States
• GSK Investigational Site — Chaska, Minnesota, United States
• GSK Investigational Site — Tuscaloosa, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.